20.03USD-1.04%Mkt Cap: 2.90B USDP/E: —Last update: 2026-05-26
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative prot…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap2.90B USD
Enterprise Value2.78B USD
Revenue (TTM)56.99M USD
Gross Profit-72.27M USD
Net Income (TTM)-101.59M USD
Revenue/Share0.4580 USD
Last Price20.03 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees137
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-13.66
PEG—
EV/EBITDA-24.09
EV/Revenue48.78
P/S54.87
P/B8.49
EPS (TTM)-0.83
EPS (Forward)-1.58
52W Range
1.79069% of range28.41
52W High28.41 USD
52W Low1.790 USD
Profitability
Gross Margin-126.80%
Oper. Margin-206.22%
EBITDA Margin-202.50%
Profit Margin-162.85%
ROE-29.35%
ROA-25.48%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-138.89M USD
CapEx (TTM)1.05M USD
FCF Margin-119.73%
FCF Yield-2.35%
Net Debt-347.05M USD
Net Debt/EBITDA3.01
Balance Sheet
Debt/Equity0.10
Current Ratio27.38
Quick Ratio26.51
Book Value/Sh2.547 USD
Cash/Share2.626 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)31.90 USD
Target Range21.00 USD – 55.00 USD
# Analysts10
Ownership
Shares Out.144.65M
Float69.50M
Insiders1.38%
Institutions126.93%
Short Interest
Short Ratio12.9d
Short % Float26.87%
Short % Out.26.52%
Shares Short38.25M
Short (prev mo.)40.37M
Technical
SMA 5022.01 (-9.0%)
SMA 20012.55 (+59.6%)
Beta1.22
S&P 52W Chg28.31%
Avg Vol (30d)3.07M
Avg Vol (10d)3.08M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—